BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for
BioCardia got the FDA to accept its plan for a medical device. This means the company is moving forward toward getting official permission to sell it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.